Novo Nordisk reported forecast-beating third-quarter sales of its popular Wegovy weight-loss drug on Wednesday, reassuring ...

Novo Nordisk said the side effects in trials so far for its experimental obesity drug CagriSema were similar to its GLP-1 ...

The company narrowed its full-year guidance as its blockbuster weight-loss drug soars in popularity.

Excitement is building around a new weight loss drug, CagriSema, which is expected to surpass the effects of popular drugs ...

A mixed sales report for Novo Nordisk’s GLP-1 megablockbuster drugs failed to quiet concerns Wednesday that investors may ...

Analysts have struggled to estimate the size of the compounded market for weight-loss drugs because their sale is not tracked ...

Novo Nordisk (NVO) is aware of 10 deaths and 100 hospitalizations of people that took copycat versions of its popular drugs ...

Novo Nordisk A/S’s Wegovy helped treat an obesity-associated liver disease in a late-stage trial, potentially adding to its ...

Novo Nordisk's popular weight-loss injection Wegovy and diabetes drug Ozempic, both known chemically as semaglutide, were — until recently — in shortage in the United States. Given all the U.S ...

it took another four years for Wegovy to be approved for weight loss. It turned Novo Nordisk from niche player, to a company bigger than Coca Cola and Procter and Gamble… The CEO is Lars ...

Novo Nordisk addresses safety concerns surrounding compounded versions of its weight-loss and diabetes drugs, including ...